Injectable knee filler for osteoarthritis pain relief
Part of Bones, joints & muscles clinical trials.
This trial tests a new injectable filler called ALLOHEAL, injected directly into the knee joint to reduce pain and improve function in people with knee osteoarthritis. The filler is designed to cushion the knee joint and may help reduce pain and stiffness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–79 years old
- Diagnosed with knee osteoarthritis (mild to moderate severity on X-ray)
- Knee pain for at least 8 weeks with a pain score of 40 or higher
- BMI under 35 kg/m² (height and weight within a healthy range)
- Able to walk without a walker or cane (unless you've been using one for 6+ months)
- No recent knee surgery in the past 6 months and no severe knee damage, instability, or skin problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NPNP-001 for people with knee osteoarthritis who have not gotten enough relief from other treatments. The medicine is given as an injection into the knee to see if it can reduce pain and improve function.
This study tests whether a hyaluronic acid injection (a natural lubricant for joints) can reduce inflammation markers in the knee for people with osteoarthritis. It may be a good option if you have moderate knee pain that hasn't improved with other treatments.
This early-phase study tests an injection of donor stem cells placed into the knee joint to help reduce symptoms of knee osteoarthritis. You may be eligible if you have long-lasting knee pain from mild-to-moderate arthritis and meet safety and imaging requirements.
This trial tests a new stem cell treatment (NCR100) for knee osteoarthritis. It aims to see if the injection can reduce pain and improve knee function in people with moderate knee OA.
This trial tests an injectable medication called RAB001 for people with knee osteoarthritis that hasn't improved with other treatments. The goal is to see if it's safe and helps reduce pain.
This study tests a new cell-based injection (Allocetra) directly into the knee joint for people with moderate osteoarthritis who haven't benefited from other treatments. The goal is to reduce pain and improve knee function.
Hear when a new Knee Osteoarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.